Vascular Inflammation and Cholesterol Lowering Therapy
- Sponsor
- Rigshospitalet, Denmark
- Study ID
- NCT02941016
- Phase
- PHASE4
- Status
- Withdrawn
Conditions
- Lipid Lowering, Vascular Inflammation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Evolocumab or Alirocumab — DRUGAll patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
Study Details
This study aim to detect change in vascular inflammation following intense lipid lowering therapy
Key Dates
- Start date
- Oct 31, 2016
- Status verified
- Oct 2020
- Primary completion
- Oct 31, 2020
- Completion
- Oct 1, 2020
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Lipid lowering
Primary Outcome Measure
Change in vascular inflammation [ Time Frame: 12 weeks ]